Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 8975 results

  1. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Ciclosporin ophthalmic solution for treating dry eyes after inadequate response to artificial tears [TSID8472]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. NVK-002 for treating myopia in people 3 to 17 years [TSID11961]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Natural Cycles for monitoring fertility

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Arthrosamid for symptomatic treatment of knee osteoarthritis

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. Lonafarnib for treating progeria and progeroid laminopathies [ID3867]

    Topic prioritisation

    Highly specialised technologies guidance
    Topic prioritisation

  10. Lumella Pre-Eclampsia Test (MT687)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  11. Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654]

    In development Reference number: GID-TA11866 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Vamikibart for treating uveitic macular oedema [ID6671]

    Awaiting development Reference number: GID-TA11885 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658]

    Awaiting development Reference number: GID-TA11868 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]

    Awaiting development Reference number: GID-TA11862 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Prostate cancer: diagnosis and management (update)

    In development Reference number: GID-NG10451 Expected publication date: TBC

    NICE guideline
    In development